Video

Dr. Brufsky on Trastuzumab Biosimilars in Breast Cancer

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the utility of trastuzumab (Herceptin) biosimilars in breast cancer.

Currently, 5 trastuzumab biosimilars have been approved by the FDA for use in HER2-positive breast cancer.

There may be subtle differences among the individual agents; however, the drugs should be considered the same, says Brufsky.

Selecting the optimal agent will ultimately come down to availability and cost rather than medical factors, he concludes.

Related Videos
Dasom (Caroline) Lee, MD
William K. Oh, MD
Olalekan O. Oluwole, MD
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Axel Merseburger, MD, PhD
Shilpa Gupta, MD
Drs Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD